| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943788 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2027
(3 years from now) | |
| US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(3 years from now) | |
| US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(11 months from now) | |
| US10617668 | JANSSEN PHARMS | Pharmaceutical formulations |
May, 2031
(7 years from now) | |
Invokana is owned by Janssen Pharms.
Invokana contains Canagliflozin.
Invokana has a total of 5 drug patents out of which 0 drug patents have expired.
Invokana was authorised for market use on 29 March, 2013.
Invokana is available in tablet;oral dosage forms.
Invokana can be used as reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients, reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients with 100 mg canagliflozin per day, reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients.
Drug patent challenges can be filed against Invokana from 29 March, 2017.
The generics of Invokana are possible to be released after 11 May, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-809) | Sep 27, 2022 |
| New Indication(I-733) | May 20, 2019 |
| M(M-197) | Feb 01, 2020 |
| New Indication(I-788) | Oct 29, 2021 |
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
Drugs and Companies using CANAGLIFLOZIN ingredient
NCE-1 date: 29 March, 2017
Market Authorisation Date: 29 March, 2013
Treatment: Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients; Reductio...
Dosage: TABLET;ORAL
INVOKANA family patents
